Φορτώνει......

Radiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors()

PURPOSE: Advanced NSCLC harboring epidermal growth factor receptor (EGFR) mutations treated with EGFR tyrosine kinase inhibitors (TKIs) typically progresses after initial response due to acquired resistance. TKIs are often continued beyond progressive disease by RECIST. We investigated the practice...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς: Nishino, Mizuki, Cardarella, Stephanie, Dahlberg, Suzanne E., Jackman, David M., Ramaiya, Nikhil H., Hatabu, Hiroto, Rabin, Michael S., Jänne, Pasi A., Johnson, Bruce E.
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: 2012
Θέματα:
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3580850/
https://ncbi.nlm.nih.gov/pubmed/23254265
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.lungcan.2012.11.007
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!